AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best stocks under $5 with huge upside potential. Guggenheim lifted the price target on AtaiBeckley Inc. (NASDAQ:ATAI) to $16 from $11 on April 17, maintaining a Buy rating on the shares. The firm told investors that its recent meetings with management reinforced its “conviction” in the BPL-003 program heading into Phase 3 initiation this quarter.
In another development, AtaiBeckley Inc. announced on April 8 peer-reviewed Phase 2a results in CNS Drugs, exhibiting that a single intranasal dose of BPL-003 attained rapid and sustained reductions in MADRS scores from baseline in participants with treatment-resistant depression who remained on stable SSRI therapy throughout the study. BPL-003 holds FDA Breakthrough Therapy Designation.
Management reported that A 66.7% antidepressant response rate was observed at Day 2 in both the 10 mg (n=6) and 12 mg (n=6) cohorts, with 83% of participants in the 10 mg cohort and 66.7% of participants in the 12 mg cohort maintaining a response at Week 12.
Headquartered in Germany, AtaiBeckley Inc. is a clinical-stage biopharmaceutical company focused on treating mental health disorders.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
